Collaborative EDNAP exercise on the IrisPlex system for DNA-based prediction of human eye colour
Chaitanya, L; Andersen, Jeppe Dyrberg; Morling, Niels; Kayser, Manfred

Published in:
Forensic Science International: Genetics

DOI:
10.1016/j.fsigen.2014.04.006

Publication date:
2014

Citation for published version (APA):
Collaborative EDNAP exercise on the IrisPlex system for DNA-based prediction of human eye colour

Lakshmi Chaitanya a,1, Susan Walsh a,1,2, Jeppe Dyrberg Andersen b, Ricky Ansell c, Kaye Ballantyne d, David Ballard e, Regine Banemann f, Christiane Maria Bauer g, Ana Margarida Bento h, Francesca Brisighelli i, Tomas Capal j, Lindy Clarisse k, Theresa E. Gross l, Cordula Haas m, Per Hoff-Olsen n, Clémence Hollard o, Christine Keyser o, Kevin M. Kiesler p, Priscila Kohler q, Tomasz Kupiec q, Adrian Linacre r, Anglika Minawi f, Niels Morling b, Helena Nilsson s, Lina Norén c, Renée Ottens f, Jukka U. Palo t, Walther Parson g, Vincenzo L. Pascali i, Chris Phillips h, Maria João Porto h, Anti Sajantila t,v, Peter M. Schneider i, Titia Sijen k, Jens Söchtig u, Denise Syndercombe-Court e, Andreas Tillmar s, Martina Turanska w, Peter M. Vallone p, Lívia Zatkalíková w, Anastassiya Zidkova x,y, Wojciech Braničik z, Manfred Kayser a,l

a Department of Forensic Molecular Biology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands
b Swedish National Laboratory of Forensic Science, Linköping, Sweden
c Department of Forensic Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
d Swedish National Laboratory of Forensic Science (SKL), Linköping, Sweden
e Forensic Services Department, Victoria Police, Malvern, Victoria, Australia
f Department of Forensic and Analytical Science, School of Biomedical Sciences, King’s College London, United Kingdom
g Forensic and Analytical Science Laboratory, University of Iceland, Reykjavik, Iceland
h Institute of Legal Medicine, Innsbruck Medical University, Innsbruck, Austria
i Serviço de Genética e Biologia Forense, Delegação do Centro, Instituto Nacional de Medicina Legal, Coimbra, Portugal
j Forensic Genetics Laboratory, Institute of Legal Medicine, Università Cattolica del Sacro Cuore, Rome, Italy
k Department of Forensic Genetics, Institute of Criminalistics, Prague, Czech Republic
l Department of Human Biological Traces, Netherlands Forensic Institute, The Hague, The Netherlands
m Institute of Legal Medicine, Faculty of Medicine, University of Cologne, Cologne, Germany
n Institute of Legal Medicine, University of Zurich, Zurich, Switzerland
o Department of Forensic Biology, Norwegian Institute of Public Health, Oslo, Norway
p Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden
q Laboratoire d’Anthropologie Moléculaire, Université de Strasbourg, Institut de Médecine Légale, Strasbourg, France
r Material Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA
s Section of Forensic Genetics, Institute of Forensic Research, Kraków, Poland
t School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
u Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden
v Department of Forensic Medicine, Hjelt Institute, University of Helsinki, Helsinki, Finland
w Forensic Genetics Unit, Institute of Legal Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
x Section of Forensic Genetics, Department of Forensic and Investigative Genetics, University of North Texas Health Science Center, Fort Worth, TX, USA
y Institute of Forensic Science, Ministry of the Interior, Department of Biology and DNA Analysis, Slovenská Lupca, Slovakia
z Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
a Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
b Department of Genetics and Evolution, Institute of Zoology, Jagiellonian University, Kraków, Poland

corresponding author. Tel.: +31 10 7038073; fax: +31 10 7044575.
E-mail address: m.kayser@erasmusmc.nl (M. Kayser).

These authors contributed equally to this work.

Current affiliation: Yale Molecular Anthropology Laboratory, Department of Anthropology, Yale University, 10 Sachem Street, New Haven, CT 06511, USA.

http://dx.doi.org/10.1016/j.fsigen.2014.04.006
1872–4973 © 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction

The field of forensic genetics is making great strides with the rapid scientific and technological evolution in obtaining new knowledge and creating innovative tools for solving crimes more and more effectively. Forensic DNA Phenotyping (FDP), a nascent advancement in this field, is one example of recent innovative developments in forensic genetics and involves the prediction of an individual’s externally visible characteristics (EVCs) using biological samples obtained at a crime scene or from an anonymous body (parts) that may belong to a missing person [1–4]. Conventional DNA identification involves the comparison of DNA profiles derived from short tandem repeat (STR) marker genotypes obtained from evidence and reference samples, which is useful in cases when the sample donor is known from their DNA profile. In certain circumstances, sample donors may not be identified, i.e. a match (or familial match) of the DNA profiles with known suspects such as those in criminal offender DNA (profile) databases or with ante-mortem samples in cases of missing persons is not successful, or when DNA profile comparisons with putative relatives of missing persons does not reveal the degree of similarities indicating biological relationship. In these situations, FDP can be used to help investigative authorities focus their search for unknown suspects or missing persons towards individuals with particular DNA-predicted externally visible phenotypes. The DNA-based prediction of EVCs can thus aid investigations by police and other authorities by reducing the number of possible suspects or other individuals if conventional STR typing of the evidence fails to produce identification [1,2]. Furthermore, reconstructing appearance information from biological samples such as bones or teeth or other remains of deceased individuals is relevant in anthropological research disciplines including those relying on ancient DNA analysis [1,2,5].

Several model-based approaches, amongst others [4,6], have been developed for predicting a particular phenotype from DNA most notably human eye (iris) colour [7]; the IrisPlex system is one such tool [8]. IrisPlex can accurately predict blue and brown eye colour with a precision of >94%, according to a previous study [9], using six of the most informative eye colour markers: rs12913832 (HERC2), rs1800407 (OCA2), rs12896399 (SLC24A4), rs16891982 (SLC45A2 (MATP)), rs1393350 (TYR) and rs12203592 (IRF4) in a single genotyping assay and a prediction model based on thousands of individuals for which IrisPlex genotype and eye colour phenotype data are available [7,8,10]. The 94% accuracy is based on using a threshold of $p > 0.7$, however it is possible to use IrisPlex prediction with a lower $p > 0.5$ threshold. The assessment of precision accuracy is based on a broad European dataset of >3800 individuals using IrisPlex can be found in Table 3 of that publication [9]. The IrisPlex assay represents the first FDP system that successfully underwent developmental validation using the Scientific Working Group on DNA Analysis Methods (SWGDAM) guidelines for use in forensic casework [10]. The IrisPlex prediction model, first established on thousands of Dutch Europeans, has been evaluated in several populations within and outside Europe and was shown to perform reliably, independent of the bio-geographic origin of the individual tested [9,11].

In an international effort to test the reliability and consistency of the IrisPlex system for eye colour prediction through an international exercise, the European DNA Profiling (EDNAP) Group, a working group of the International Society for Forensic Genetics (ISFG), carried out a collaborative study led by the Department of Forensic Molecular Biology of the Erasmus University Medical Center Rotterdam (Netherlands), who initially developed and validated the IrisPlex system [8–10] and for this reason were chosen to conduct this further assessment on the IrisPlex tool alone. Of the 21 participating laboratories, 18 were from Europe,
2 were from Australia and 1 was from the U.S.A. The prime aim of this exercise was to implement the method and assess the performance of the system across different forensic laboratories with varying levels of experience, from complete novices with no SNP typing experience to participants with SNAPSHOT experience and those with specific IrisPlex experience.

Notably, some authors previously raised issues about marker content and model outcomes of the IrisPlex system [12–15]. The present collaborative EDNAP exercise, however, represents a rather technical exercise to test the performance of the IrisPlex system across laboratories with varying levels of pre-existing experience. Therefore, issues about marker and model choice for predicting eye colour from DNA may be addressed in more dedicated future studies. Here, we present the results of this collaborative EDNAP exercise, placing emphasis on the reliability and consistency in using the IrisPlex system for blue and brown eye colour prediction from DNA.

2. Materials and methods

2.1. Samples and materials provided to the participating laboratories

The organising laboratory (Department of Forensic Molecular Biology, Erasmus MC University Medical Center Rotterdam, Netherlands) divided the entire exercise into three different tasks. All participants were provided with a detailed written laboratory protocol [8] as well as the eye colour prediction model that is an interactive excel spreadsheet as published earlier [10]. Furthermore, for assay interpretation guidelines, participants were given a protocol stating a 50 relative fluorescent units (rfu) peak height threshold should be used for allele calls using the IrisPlex specific GeneMapper software (Applied Biosystems) Bin and Panel set provided. For a broader understanding of average peak heights and balance ratios, participants were asked to refer to the most recent published development validation of the IrisPlex system [10]. In addition to the samples and the primers provided for each task, all reagents, which include: 1 × PCR buffer, 2.7 mM MgCl₂, 200 mM of each dNTP, 0.5 U AmpliTaq Gold Polymerase, SNAPSHOT Multi-plex chemistry for the single base extension (SBE) reactions (Applied Biosystems, Foster City, CA), Exonuclease Shrimp Alkaline Phosphatase (ExoSAP-IT), and Shrimp Alkaline Phosphatase (SAP) (USB Corporation, Cleveland, OH), required for running the IrisPlex system were shipped on dry ice to each of the 21 participating laboratories. The laboratories were asked to use their own internal sizing standard (LIZ 120) and formamide for the capillary electrophoresis run.

Due to an ExoSAP-IT™ degradation issue noted during the early phase of the exercise, which subsequently was acknowledged by the producing company as a bad batch of enzyme, aliquots of a newly delivered and tested ExoSAP-IT™ were shipped again to the requesting laboratories, while the others opted to use their in-house standard cleaning protocols. As this was a clean-up procedure, it did not impede on the testing of the IrisPlex assay overview. Purified products were run by the laboratories using their in-house Genetic Analyser (for type, see Table 1) and analysed with the previously published eye colour prediction model [10] provided by the organising laboratory for predicting human eye colour from IrisPlex genotypes.

As a disclaimer for the choice of samples used in this assessment, please note that it is well established and documented [7,9,16,17], that the IrisPlex system through its use of six eye colour associated SNPs performs very well in predicting blue and brown eye colour with Area Under the Receiver operator Curve (AUC) values >0.9; however its use for predicting intermediate eye colour (current AUC of ~0.7) is not at an optimum level yet. This is due to the current lack of knowledge on DNA predictors for these non-blue, non-brown eye colours i.e. green eye colour, individuals with heterochromia etc. which is not only a limitation of the IrisPlex but of all currently available DNA test systems for eye colour [4,6]. DNA variation with similarly high prediction effects on non-blue/brown eye colours as the IrisPlex SNPs have on blue and brown eye colour have yet to be identified. Therefore, the IrisPlex system was previously promoted for the prediction of blue and brown eye colours and thus the organising laboratory opted to test variations in blue and brown eye colour alone for Tasks 1 and 2 to evaluate the current IrisPlex system assay and prediction performance on these categories. Task 3 however incorporates all three categories as this task was based on samples provided by the participating laboratories who were not asked to focus on blue and brown eye colour alone when selecting their Task 3 volunteers.

Tasks 1 and 2 contain samples from individuals of European (80% per task) and non-European bio-geographic origin (20% per task) including one admixed individual in Task 1. The individuals used in Task 3, including information about their bio-geographic background, were at the discretion of the participating laboratories and were unknown to the organising lab.

2.2. Task 1 – IrisPlex eye colour prediction from biological samples with eye colour knowledge

The organising laboratory provided all participating laboratories with five blood samples (labelled Ind1–Ind5) and five saliva

| Table 1 | DNA extraction and quantification protocols used by the 21 laboratories for both Tasks 1 and 2. Grey boxes indicate no data received from the participating laboratory. |
|---|---|---|---|---|
| Lab ID | Extraction Protocol | Quantification Protocol | Polymer | Genetic Analyzer |
| 1 | EZI DNA Investigator kit (Qiagen) | Quantifier Duo DNA Quantiﬁcation kit (Life Technologies) | POP 6 | POP 6 |
| 2 | EZI DNA Investigator kit | Quantifier Duo DNA Quantiﬁcation kit | POP 6 | POP 6 |
| 3 | Qiagen EZ1 Advanced XL (Qiagen) | Quantifier Duo DNA Quantiﬁcation kit | POP 6 | POP 6 |
| 4 | Task 1: EZI advanced (Qiagen); Task 2: DNA Maxi Kit (Qiagen) | All primers: 7900 (Life Technologies) using Quantifier® Human DNA Quantiﬁcation Kit (UT) | POP 6 | POP 6 |
| 5 | Chelex (Chelex) | Task 1: Qyt and Task 2: RT-PCR Quantifier® | POP 6 | POP 6 |
| 6 | Qiagen DNA Maxi Kit (Qiagen) | tPCR using the 7900HT Fast Real-Time PCR System, Applied Biosystems (Foster City, CA) and ABS PreMix | POP 6 | POP 6 |
| 7 | Qiagen DNA Maxi Kit (Qiagen) | tPCR using the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) and ABS PreMix | POP 6 | POP 6 |
| 8 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 9 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 10 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 11 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 12 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 13 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 14 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 15 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 16 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 17 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 18 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 19 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 20 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
| 21 | Qiagen DNA Maxi Kit (Qiagen) | Quantifier Duo | POP 6 | POP 6 |
samples (labelled Ind6–Ind10) on FTA cards of 10 individuals with blue \((N = 5)\) or brown \((N = 5)\) eye colour. To produce these samples, fresh venous blood and saliva samples were collected from ten different individuals and 100 \(\mu L\) of each of the samples were pipetted on to the FTA cards. A digital image eye from each of these 10 individuals who donated blood or saliva was also provided to the participants. All the laboratories were instructed to use their own in-house DNA extraction and quantification protocols. All participating laboratories were asked to generate the IrisPlex genotype profile from each of the 10 samples and using the provided IrisPlex prediction model, to conclude the eye colour prediction of the 10 donor individuals by noting the probability and precision accuracy per each sample and individual using the guidelines implemented in a previous publication [9] as provided to the participants. An example report was also provided to each laboratory to ease the fill-out for return. As the participants were provided with eye pictures, they already knew the eye colour of the study individuals of Task 1 before analyses. However, the conclusion of the eye colour phenotypes had to be based on the genotypes determined by each individual laboratory considering the probability and precision accuracy guidelines provided by the organising laboratory. The term ‘precision accuracy’ relates to the previous publication [9], which undertook a study on the final prediction called by the IrisPlex model in terms of probability values on over 3800 European individuals. It assesses the highest probability value (which is defined as the eye colour of the individual) and how correct the eye colour prediction was at thresholds that increase in increments of 0.05; from no threshold to \(p > 0.95\) [9].

### 2.3. Task 2 – IrisPlex eye colour prediction from DNA of simulated casework samples without eye colour knowledge

The laboratories were provided with five DNA samples extracted from simulated casework samples (labelled CW1–CW5) from 5 individuals with blue \((N = 2)\) or brown \((N = 3)\) eye colour. DNA samples were extracted by the organising laboratory with the QiAamp DNA mini kit (Qiagen, Hagen, Germany). The following biological materials were used for DNA extractions: 2 buccal swabs (CW1 and CW2) – both samples subjected to UV radiation using the Bio-Link (Vilber Lourmat) for 1 min at a strength of 50J/cm\(^2\) before DNA extraction; saliva on glass slide (CW3) stored at room temperature for 1 week before DNA extraction, whole blood on glass slide (CW4) stored at room temperature for 1 week before DNA extractions, and semen DNA extracted from a frozen donated sample (CW5). DNA concentrations were measured using the nanodrop system and 3 \(\mu L\) of the following solutions were provided: CW1: 0.5 ng/\(\mu L\); CW2: 0.1 ng/\(\mu L\); CW3: 0.25 ng/\(\mu L\); CW4: 2 ng/\(\mu L\), and CW5: 50 ng/\(\mu L\) (see Table 2 for overview). The samples CW1–CW4 were freshly extracted, quantified and run using the IrisPlex system prior to DNA degradation, thereby serving as a control to their degraded counterparts. In contrast to Task 1, in Task 2 the laboratories were not provided with any eye colour phenotype information of the sample donors. Participants were also not provided with any other sample information such as DNA concentration or treatment prior to DNA extractions of the DNA extracts they received for Task 2. They were asked to generate the IrisPlex genotype profile for each individual and report back the obtained eye colour probabilities and accuracies using the model and materials provided, and to finally conclude the most likely eye colour category per individual. An example report was also provided.

### 2.4. Task 3 – participant-driven IrisPlex eye colour prediction

This part of the study was optional. Each participating laboratory was instructed to collect and genotype samples from five different individuals of any eye colour. Selection of volunteers and biological materials was at the discretion of the participants. An important caveat in this task is that IrisPlex cannot guarantee a high prediction accuracy of the non-blue and non-brown eye colours; however, in contrast to Tasks 1 and 2 no eye colour phenotype restrictions were imposed on the participants in their choice of volunteers for Task 3. The laboratories were asked to report the DNA concentration, IrisPlex genotypes, eye colour probability outcomes and accuracy percentages, and a digital high-resolution eye image of the genotyped individuals. The organising laboratory instructed that the iris photo should be taken in natural light conditions (no fluorescent bulb light) with and without flash lens using a digital camera focusing on eyes only (no full portrait).

### 3. Results and discussion

#### 3.1. Sample extractions and quantifications by each participating laboratory

As the DNA extraction and quantification method can influence genotyping outcomes due to the quality and quantity of DNA extracted and consequently input into a downstream reaction, it can thus influence phenotype inference from the genotypes produced in FDP systems. Therefore we included extraction and quantification monitoring in this exercise. As part of Task 1, the host laboratory provided the participating laboratories with biological samples (blood and saliva samples on FTA cards) from which the participants extracted and quantified DNA using their methods of choice. To note, the affiliated laboratory number in the author list does not represent the laboratory number described throughout the paper. Protocols used for DNA extraction and quantification were different and are listed in Table 1. As evident, the different extraction and quantification methods used by the participating laboratories provided varying results, as summarised in a box plot diagram (Fig. 1), even though the same volume of biological sample was provided to each of the participants on FTA cards. Labs #2, 4, 13, 14 and 17 used the Qiagen EZI investigator kit for extraction and reported on average higher quantification values as compared to Labs #6, 9, 10, 12 and 15 that used the Qiagen QIAamp DNA mini kit extraction protocol. Lab #20 applied a Phenol–Chloroform extraction approach, which yielded on average higher quantification values compared to all the other methods used. Lab #18 used the PrepFiler Forensic DNA extraction kit and obtained on average higher final DNA amounts than all other methods, except Phenol–Chloroform. Labs #5, 7, 8, and 19, which used the Chelex extraction protocol, reported comparatively lower quantification values than all other methods used in this exercise. Worthy to note, this figure assumes that all laboratory input DNA volumes were similar (i.e. the recommended 1 \(\mu L\)). The precise extraction volumes used by all labs were not available to the organising laboratory. This figure merely represents the differing extraction methods yielding varying final DNA concentrations; however, it is expected that the participants followed all recommendations provided by the organising lab which specifically states a 1 \(\mu L\) volume with at least a concentration of 32 pg
DNA input for IrisPlex profiling. The DNA samples provided for Task 2 were previously extracted by the host laboratory using the QIAamp DNA mini kit (Qiajen). The participating laboratories were requested to measure DNA concentrations using their method of choice and to report back the values. Because different quantification methods were used, the obtained concentration estimates differed (Fig. 1 and Supplementary Table 1), similar to Task 1, even though equal aliquots of the very same DNA solutions per each sample were provided to each of the participants. As evident, sample CW2 was recorded as the most variable (0.01–2.61 ng/μL), which contradicts recorded measurements by the organising laboratory of 100 pg (Fig. 1).

Supplementary material related to this article can be found, in the online version, at doi:10.1016/j.fsigen.2014.04.006.

Overall, the recorded DNA quantification data indicate that all samples shipped, both the biological samples on FTA cards of Task 1 and the extracted DNA samples of Task 2, and remained rather stable during transportation and short-term storage at the participating laboratories. For the impact of the varying amounts of DNA obtained by the participants in Task 1 and the varying DNA concentration measures obtained in Task 2 on genotype and phenotype accuracy, see the specific chapters on Tasks 1 and 2 below. From the DNA quantification data reported by the participating laboratories for the samples used in Task 3 (Supplementary Table 1) it is evident that all the samples genotyped for this portion of the exercise were of reasonable quantity. When conducting genotyping analyses and calling the peaks, the 50 rfu fluorescence threshold was set for calling alleles for a locus in all tasks and samples.

3.2. Task 1 – IrisPlex eye colour prediction from biological samples with eye colour knowledge

All participating laboratories reported the predicted eye colour and their probabilities in the format as requested by the organising laboratory. Fig. 2 depicts the accurate genotype and eye colour phenotype calls for all the ten samples as obtained by the 21 participating laboratories. Supplementary Table 2 lists the genotypes of the ten individuals with their respective eye colour probability and accuracy. Fig. 3 shows the eye colour images of the 10 individuals used in this task.

Supplementary material related to this article can be found, in the online version, at doi:10.1016/j.fsigen.2014.04.006.

Twenty of the 21 laboratories (95%) predicted the eye colour of all 10 individuals included in Task 1 correctly from IrisPlex (Fig. 2; green bars). Overall, 208 (99%) of the 210 samples analysed in this task by all the 21 laboratories were reported with the correct eye colour phenotype prediction. An overview of the samples with incorrect genotypes that were discordant with the organising laboratory is provided in Table 3. Only one laboratory (Lab #3) faced difficulties in concluding the correct eye colour phenotype for two samples (Individual 1 and 10). The phenotype for both
individuals was reported as inconclusive, although the correct IrisPlex genotypes were obtained and reported. These two individuals had eye colour probabilities for blue, intermediate and brown of 0.306, 0.142, 0.552 and 0.299, 0.253, 0.448 respectively (Fig. 3(a) and (k)), and did not cause a problem for the other 20 laboratories to conclude the correct brown eye colour for both samples.

Overall, 1253 (99.4%) of the 1260 genotypes generated for the 6 IrisPlex SNPs in the 210 samples analysed by all the 21 laboratories were reported correctly. The 7 (0.6%) incorrect genotypes were reported by 4 laboratories, while 17 participants reported the correct 6-SNP IrisPlex profiles for all 10 samples. Importantly, none of these incorrect genotypes led to erroneous eye colour phenotype predictions being reported. Lab #7 reported an incorrect homozygous genotype T instead of the true heterozygous CT for rs12203592 for Individual 8 due to a dropout of the C allele, since the respective peak was below the 50 rfu threshold. Lab #12 reported discordant heterozygous instead of correct homozygous genotypes for Individual 9 across three markers (rs12913832, rs16891982 and rs1393350). Drop-in of the alleles C, G and T was observed for each of the markers rs12913832, rs16891982 and rs1393350 respectively. However, the DNA concentration for this particular sample was reported by Lab #12 to be very low (0.02 ng/μL), much lower than the concentration obtained by the other

---

**Fig. 2.** Accuracy of the IrisPlex genotype calls (6 SNPs) and the IrisPlex-based eye colour phenotype prediction of the 10 samples provided in Task 1 as reported by each of the 21 participating laboratories. Blue indicates the number of individuals that were correctly genotyped at all 6 IrisPlex SNPs (i.e. for which a correct IrisPlex profile was reported). Red indicates the total number of genotypes across all 6 SNPs and all 10 samples that were correctly reported. Green indicates the number of individual samples for which the correct eye colour phenotype was reported. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of the article.)

**Fig. 3.** Eye colour images of the 10 individuals whose samples were used in Task 1 and the 5 individuals whose samples were used in Task 2. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of the article.)
laboratories for this sample (Supplementary Table 1). In accordance with the provided protocol, 1 μL of DNA solution of this sample was used for the IrisPlex PCR. Therefore, for this sample the amount of DNA input was below the previously established sensitivity threshold of the IrisPlex assay [10], which explains the high failure rate for genotypes of this sample. Lab #15 reported incorrect homozygous genotype of the G allele (instead of the correct heterozygous GC genotype) for individual 2 as rs16891982 due to a dropout of the C allele. Lab #18 experienced at marker rs12203592 a drop-in of allele T for individual 3 and dropout of allele T in individual 8. One explanation could be primer degradaion due to incorrect storage of the primer or an incorrect volume addition of this primer to the assay, but unlikely due to a sample issue as the DNA concentrations reported for the individuals 2, 3 and 8 by the Labs #15 and 18 were more than 1.1 ng/μL (provided that the correct input of 1 μL was used). For cases such as these, an erroneous result can be avoided by re-running several analyses of the sample, and is usually recommended when using all genotyping platforms, this includes the IrisPlex system.

### 3.3. Task 2 – IrisPlex eye colour prediction from DNA of simulated casework samples without eye colour knowledge

In Task 2, the provided five DNA extraction aliquots from simulated casework samples (Table 2) were evaluated by each participating laboratory. Notably, the samples used for DNA extractions not only came from different biological sources (saliva, blood, and semen) but also experienced different environmental conditions (UV radiation, storage at room temperature) and were provided to the participants in varying DNA concentrations (0.1–50 ng/μL), all unknown to the participants. Therefore, and due to the fact that no eye colour phenotypes were provided of the sampled individuals, this task was more challenging than Task 1. Fig. 4 depicts the accurate genotype and eye colour phenotype calls for all the 5 samples as reported by the 21 participating laboratories. Supplementary Table 2 shows the reported genotypes of the five samples with their respective eye colour prediction probabilities and precision accuracy. Fig. 3 shows the eye colour images of the 5 individuals used in this task. An overview of the samples with incorrect genotypes that were discordant with the organising and the other participating laboratories is provided in Table 3.

Eighteen (86%) of the 21 laboratories predicted the eye colour of all 5 individuals correctly from IrisPlex (Fig. 4; green bars). Overall, 101 (86.2%) of the 105 samples analysed by all the 21 laboratories together were reported with the correct eye colour phenotype. The 4 samples (3.8%) for which the eye colour phenotypes were incorrect had been reported by 3 laboratories. Lab #3 predicted the eye colour of 2 of the 5 individuals (CW2 and CW3) as inconclusive, although the genotypes for these samples were reported correctly. Both samples clearly had to be designated as brown from the obtained probabilities (p = 0.448 and p = 0.552, respectively), and the phenotypes indeed were brown (Fig. 3[1] and [m] respectively), as was correctly interpreted by 18 other laboratories. The other 2 incorrectly phenotyped samples were reported by Labs #6 and 17 due to the drop-out of the T allele at rs12913832 in sample CW2. The 2 laboratories reported an incorrect homozygous C allele instead of a heterozygous CT allele, thereby, reporting an incorrect blue eye colour instead of the correct brown eye colour phenotype (Fig. 3[1]).
Overall, 622 (98.7%) of the 630 genotypes generated for the 6 IrisPlex SNPs in the 105 samples analysed by all laboratories together were correctly reported in Task 2. The 8 (1.3%) incorrect genotypes were produced in 2 samples (CW2 and CW3) by 6 laboratories, while 15 of the 21 laboratories (71.4%) reported the correct 6-SNP IrisPlex profile for all 5 samples. In contrast to the 2 (25%) genotype errors in sample CW2 by Lab #6 and 17 that caused phenotype errors as mentioned in the previous paragraph, the remaining 6 incorrect genotypes (75%) did not have any impact on the eye colour phenotype accuracy. At rs12913832, Lab #7 reported an incorrect genotype due to a drop-out of the C allele for sample CW2. A drop-in of the T allele for CW2 and drop-out of the T allele for CW3 at rs1393350 resulted in incorrect genotyping by Labs #15 and 18 respectively. Furthermore, incorrect genotypes were reported by Lab #21 at rs12896399 for sample CW2 due to a drop-out of the T allele. Lab #17 experienced problems in the first typing of samples CW1, 2 and 3 and subsequently retyped these samples in different DNA dilutions. At rs12913832, drop-out of the T allele for CW2 (as mentioned above); drop-out of the C allele for CW3, and drop-out of the A allele at rs1800407 for CW2 were reported which resulted in erroneous results for this laboratory. A dilution step performed by the participating laboratory, due to a misleading quantification result, of the already low quantity degraded samples provides a likely explanation for the drop-out of the alleles in this set of samples.

Several laboratories (n = 3; Labs #3, 6 and 17) experienced difficulties with correct phenotyping of the simulated and treated casework samples in Task 2 for which no eye colour phenotypes were provided as opposed to the untreated biological samples provided together with eye colour phenotypes in Task 1 (n = 1; Lab #3). Similarly, more laboratories (n = 6; Labs #6, 7, 15, 17, 18 and 21) had difficulties in correct genotyping of Task 2 samples in relation to Task 1 samples (n = 4; Labs #7, 12, 15 and 18). Within Task 2, the most genotyping and phenotyping difficulties i.e. allelic drop-outs and drop-ins were reported for 2 particular samples (CW2 and CW3). Sample CW2 was reported with different incorrect genotypes by 5 of the laboratories (Labs #6, 7, 15, 17 and 21) and sample CW3 was reported incorrectly by 2 laboratories (Labs #17 and 18) (see Table 3 for overview). Sample CW2 must therefore be noted as being a difficult sample to genotype. From Fig. 1, it is evident that, of the laboratories that reported quantification data for Task 2, sample CW2 was recorded as the most variable (0.01–2.61 ng/μL), which strongly deviates from the recorded measurements by the organisers laboratory of 100 pg. Given its unusual quantification range, severe degradation and heterozygosity at 3 (rs12913832, rs1800407 and rs12896399) of the 6 SNPs, increased incidence of allelic drop-out may be expected in sample CW2 as compared to the homozygous sample CW1 (which also experienced UV degradation) that caused no problems for genotyping. It demonstrates, as expected and as also known for any other genotyping assay, that the combination of low quality and low quantity template DNA provides challenges for correct genotyping including for the IrisPlex assay. However, it should be emphasised that 244 of the 252 (96.8%) genotypes of the most challenging samples CW2 and CW3 were generated correctly by 15 of the 21 (71.4%) participating laboratories, which demonstrates the reliability of the IrisPlex assay for difficult DNA samples. This also represents the necessity of employing duplicate analysis when genotyping samples of low DNA quantity in final case work applications.

3.4. Task 3 – participant-driven IrisPlex testing

The optional Task 3 of the exercise, where participants were asked to recruit their own volunteers for IrisPlex genotyping and eye colour prediction, was performed by 20 of the 21 laboratories. Lab #7 could not perform this task due to reported ethical issues. Supplementary Table 3 summarises the data for this task. Based on the digital eye images provided by the participants (Fig. 5), the organising laboratory judged the correct phenotypes by two independent experienced observers. Lab #12 performed this exercise and reported the genotype and phenotype, but provided no eye images to the host laboratory for inspection. As it was not possible to judge the accuracy of the results provided by this participant, they were excluded from the analyses. As can be seen in Fig. 6, 16 of the 19 laboratories (84.2%) predicted the eye colour of all analysed individual samples correctly, while 3 laboratories faced difficulties in concluding the correct eye colour from the estimated probability combinations for some samples. Overall, 96 (96%) of the 100 samples analysed by the 19 laboratories were reported with the correct eye colour prediction, as judged by the organising laboratory based on the digital eye images sent by the participants. The 4 samples reported with incorrect eye colour were from 3 different laboratories (1x#2, 2x#3, and 1x#5). Lab #2 reported blue eye colour (p = 0.678) for their sample 1 but the eye image showed brown colour and the estimated brown eye probability was only 0.191 (Fig. 5(a)). Lab #3 obtained the following probabilities for their sample 1: Blue – 0.207, Intermediate – 0.161 and Brown – 0.632 and reported an inconclusive result, while the probability for brown was by far highest than for the other two categories so that brown should have been concluded instead and indeed the respective eye image showed brown (Fig. 5(b)). Sample 4 of Lab #3 appeared blue from the images (Fig. 5(c)) but a high brown eye probability (p = 0.892) was obtained while the blue eye probability was low (p = 0.024). Lab #5 obtained probabilities of Blue – 0.375, Intermediate – 0.264 and Brown – 0.361 for their sample 1, and reported blue eye colour but the image indicates brown eye colour (Fig. 5(d)). In this case, however, the eye colour could have been reported inconclusive since the brown and the blue eye colour probabilities were very similar. It is therefore important to use and report the level of precision accuracy based on each probability threshold with the final prediction, i.e. p = 0.5 highest probability value, p > 0.5 highest probability value. This can be found in Table 2 of our previous publication [9]. It is noteworthy to emphasise that the IrisPlex genotypes in Task 3 were not verified independently in contrast to those in Tasks 1 and 2. Therefore we cannot know for sure if any of the 4 incorrect phenotype predictions in Task 3 may have been caused by incorrect genotypes, although the high genotyping accuracy rates achieved in Tasks 1–3 suggest this might be somewhat unlikely. Due to violation of anonymity, the geographic origin of these individuals cannot be determined.

Supplementary material related to this article can be found, in the online version, at doi:10.1016/j.jfsigen.2014.04.006.

Further to note, participants for Task 3 were not asked to restrict their choice of volunteers to blue and brown eye colour only. This was different from Tasks 1 and 2 where only volunteers with blue and brown eye colour were used due to known limitations of the IrisPlex system to accurately predict non-blue and non-brown eye colours [8–10]. However only Lab #1 reported 2 individuals as intermediate (p = 0.411 and p = 0.405) and from the eye images (Fig. 5(e) and (f) respectively), we can confirm that the individuals were correctly predicted as intermediate as they contain substantial pupillary rings of a different colour (i.e. majority of iris blue colour with obvious brown pupillary ring). It is also worth noting that although no restrictions were imposed on the choice of samples for Task 3, all the laboratories (except Lab #1) chose individuals with either blue or brown eyes and hence it is most likely that all the participants were guided by knowledge of (or clearly considered the) limitations of IrisPlex for accurately predicting non-blue and non-brown eye colour phenotypes. Furthermore, according to general knowledge, the frequency of
Fig. 5. Eye images sent by the participating laboratories used for the voluntary aspect of the study, Task 3. Eye images include probability values for blue, intermediate and brown eye colour provided by the participants as determined from the IrisPlex genotypes. The area surrounded by the red lines indicates the incorrect eye colour prediction as assessed by the host laboratory from inspection of the eye images provided, and compared with the eye colour phenotype reported by the participants based on IrisPlex analysis. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of the article.)
blue and/or brown eyes is comparatively higher than intermediate in the population, which could explain the rarity of volunteers with intermediate eye colour phenotype used in Task 3.

The overall performances of the participating laboratories in all 3 tasks, is shown in Supplementary Table 4.

Supplementary material related to this article can be found, in the online version, at doi:10.1016/j.fsigen.2014.04.006.

4. Conclusions

Overall, the high level of consistency achieved throughout this collaborative effort in all 3 tasks illustrates the reliability of the IrisPlex assay in producing highly accurate 6-SNP genotypes and of the IrisPlex prediction model in producing accurate blue and brown eye colour phenotypes from IrisPlex genotypes. As shown here and previously [8], the IrisPlex assay provides reproducible results despite differing levels of experience of the laboratory personnel involved and differing DNA extraction and quantification methods used. The results obtained in this collaborative exercise demonstrate the robustness and reproducibility of DNA-based eye colour prediction when using the IrisPlex system in different forensic laboratories world-wide. As emphasised before [8–10], future focus shall be placed on improving DNA-based prediction of non-blue and non-brown eye colours, for which the IrisPlex system is less suitable than for blue and brown eye colour prediction from DNA.

Acknowledgements

We would like to thank Gabriela Huber, Nelli Roininen and Mintu Hedman for outstanding technical assistance and Vlastimir Stenzl for support. This work was funded in part by the Netherlands Forensic Institute (NFI) and a grant from the Netherlands Genomic Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) within the framework of the Forensic Genomics Consortium Netherlands (FGCN). Funding for Adrian Linacre and Renee Ottens was provided by the Attorney General’s Office, South Australia, for Theresa Gross by the EU 7th Framework Programme (FP7/2007–2013) under Grant Agreement N° 285487 (EUROFORGEN-NoE), and for Antti Sajantila by the Finnish Foundations’ Pool Professorship (Paulo Foundation).

References


